科华生物: 关于不向下修正”科华转债“转股价格的公告

Core Viewpoint - The company has decided not to adjust the conversion price of its convertible bonds, despite triggering conditions for a downward adjustment due to stock price performance [1][7]. Group 1: Convertible Bond Basic Information - The company issued 7.38 million convertible bonds with a face value of 73.8 million yuan on July 28, 2020, with the initial conversion price set at 21.50 yuan per share [2]. - The conversion price has been adjusted multiple times due to various corporate actions, with the latest adjustment resulting in a conversion price of 21.24 yuan per share [4][5]. Group 2: Downward Adjustment Clause - The downward adjustment clause for the convertible bonds is triggered if the stock price closes below 90% of the current conversion price for at least 10 out of 20 consecutive trading days [6]. - If the company decides to adjust the conversion price, it must follow specific procedures, including shareholder approval and public disclosure [6]. Group 3: Decision on Price Adjustment - The board of directors has chosen not to exercise the right to adjust the conversion price, citing confidence in the company's long-term development and market conditions [7]. - The decision will remain in effect for six months, after which the company will reassess the situation if the adjustment conditions are triggered again [7].